For research use only. Not for therapeutic Use.
GSK-2033（Cat No.:I007078）is a small molecule inhibitor that targets the histone deacetylase (HDAC) enzyme family, particularly HDAC6. It has been investigated for its potential in cancer treatment, as HDAC inhibitors can influence gene expression and promote tumor cell death. GSK-2033’s selective inhibition of HDAC6 can affect cellular processes like protein degradation, inflammation, and stress responses, which are often dysregulated in cancer. Preclinical studies suggest it may enhance the efficacy of other cancer therapies, particularly in solid tumors, though further clinical trials are necessary to confirm its therapeutic potential and safety.
| Catalog Number | I007078 |
| CAS Number | 1221277-90-2 |
| Synonyms | GSK-2033; GSK2033; GSK 2033.;2,4,6-Trimethyl-N-[[3/’-(methylsulfonyl)[1,1/’-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide |
| Molecular Formula | C29H28F3NO5S2 |
| Purity | ≥95% |
| Target | Vitamin D Related/Nuclear Receptor |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | 2,4,6-trimethyl-N-[[4-(3-methylsulfonylphenyl)phenyl]methyl]-N-[[5-(trifluoromethyl)furan-2-yl]methyl]benzenesulfonamide |
| InChI | InChI=1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4H3 |
| InChIKey | PSOXOVKYGWBTPB-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C)CC4=CC=C(O4)C(F)(F)F)C |
| Reference | </br>1:Zuercher WJ, Buckholz RG, Campobasso N, Collins JL, Galardi CM, Gampe RT, Hyatt SM, Merrihew SL, Moore JT, Oplinger JA, Reid PR, Spearing PK, Stanley TB, Stewart EL, Willson TM. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6. doi: 10.1021/jm901797p. PubMed PMID: 20345102. |
